SCHEMBL23948129

SCHEMBL23948129

Cc1cc(C#N)c(F)c(C)c1N

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EGLN2 Q96KS0 3/20 0.37
ALDH1A1 P00352 4/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
TSHR P16473 2/20 0.34
TP53 P04637 1/20 0.34
CYP3A4 P08684 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
KHK P50053 1/20 0.34
KDM4E B2RXH2 3/20 0.32
ADRB2 P07550 1/20 0.32
ADRB1 P08588 1/20 0.32
USP2 O75604 1/20 0.32
TRPV4 Q9HBA0 1/20 0.31
POLB P06746 1/20 0.31
LMNA P02545 1/20 0.31
GAA P10253 1/20 0.31
GFER P55789 1/20 0.31
AR P10275 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17687703 0.84 KHK (0.42) EGLN2ALDH1A1TSHRKHKKDM4E
SCHEMBL9821000 0.82 EGLN2 (0.35) EGLN2ALDH1A1MAPTHTTTSHR
SCHEMBL28052733 0.81 ALDH1A1 (0.39) EGLN2ALDH1A1MAPTHTTTSHR
SCHEMBL23010977 0.81 TSHR (0.38) EGLN2ALDH1A1TSHRTRPV4AR
Hydrochloric Acid SCHEMBL28047236 0.79 ALDH1A1 (0.37) EGLN2ALDH1A1MAPTHTTTSHR
SCHEMBL25871509 0.78 EGLN2 (0.35) EGLN2ALDH1A1MAPTHTTTSHR
SCHEMBL16127310 0.78 TRPV4 (0.38) EGLN2TSHRKHKKDM4ETRPV4
SCHEMBL18330714 0.78 KDM4E (0.41) ALDH1A1MAPTHTTTSHRTP53
SCHEMBL15873915 0.78 TSHR (0.35) EGLN2TSHRTRPV4AR
SCHEMBL10474259 0.76 KHK (0.42) EGLN2ALDH1A1TSHRKHKKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114315834-B Imidazolone derivatives and their use in medicine 成都百裕制药股份有限公司 2024-01-05 CN disclosed
US-20230165867-A1 IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) 2023-06-01 US disclosed
EP-4137491-A1 IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) 2023-02-22 EP disclosed
EP-4137491-A1 IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) 2023-02-22 EP disclosed
CN-114315834-A Imidazolidinone derivatives and their use in medicaments 成都百裕制药股份有限公司 2022-04-12 CN disclosed
WO-2021209055-A1 IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE 成都百裕制药股份有限公司 2021-10-21 WO disclosed
WO-2021209055-A1 IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE 成都百裕制药股份有限公司 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230165867-A1 IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF SYMPK, PAICS, CYP2C9 EGLN2 941/4885ALDH1A1 702/4885MAPT 2312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.